Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
J Hematol Oncol. 2021 Jan 6;14(1):4. doi: 10.1186/s13045-020-01017-7.
Relapse remains the main cause of treatment failure in acute myeloid leukemia (AML) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Emerging evidence has demonstrated that AML patients might benefit from maintenance therapy post-transplantation, especially for high-risk AML patients. In this mini-review, we will summarize targeted drugs, such as hypomethylating agents, FLT3 inhibitors and isocitrate dehydrogenase inhibitors, as maintenance therapy post-transplantation in AML patients undergoing allo-HSCT.
在接受异基因造血干细胞移植（allo-HSCT）的急性髓系白血病（AML）患者中，复发仍然是治疗失败的主要原因。新出现的证据表明，AML 患者可能从移植后维持治疗中获益，特别是对于高危 AML 患者。在这个迷你综述中，我们将总结移植后作为 AML 患者维持治疗的靶向药物，如低甲基化剂、FLT3 抑制剂和异柠檬酸脱氢酶抑制剂。
